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IMPORTANCE The Restart or Stop Antithrombotics Randomized Trial (RESTART) found that
antiplatelet therapy appeared to be safe up to 5 years after intracerebral hemorrhage (ICH)
that had occurred during antithrombotic (antiplatelet or anticoagulant) therapy.
OBJECTIVES To monitor adherence, increase duration of follow-up, and improve precision of
estimates of the effects of antiplatelet therapy on recurrent ICH and major vascular events.
DESIGN, SETTING AND PARTICIPANTS From May 22, 2013, through May 31, 2018, this
prospective, open, blinded end point, parallel-group randomized clinical trial studied 537
participants at 122 hospitals in the UK. Participants were individuals 18 years or older who had
taken antithrombotic therapy for the prevention of occlusive vascular disease when they
developed ICH, discontinued antithrombotic therapy, and survived for 24 hours. After initial
follow-up ended on November 30, 2018, annual follow-up was extended until November 30,
2020, for a median of 3.0 years (interquartile range [IQR], 2.0-5.0 years) for the trial cohort.
INTERVENTIONS Computerized randomization that incorporated minimization allocated
participants (1:1) to start or avoid antiplatelet therapy.
MAIN OUTCOMES AND MEASURES Participants were followed up for the primary outcome
(recurrent symptomatic ICH) and secondary outcomes (all major vascular events) for up to 7
years. Data from all randomized participants were analyzed using Cox proportional hazards
regression, adjusted for minimization covariates.
RESULTS A total of 537 patients (median age, 76.0 years; IQR, 69.0-82.0 years; 360 [67.0%]
male; median time after ICH onset, 76.0 days; IQR, 29.0-146.0 days) were randomly allocated
to start (n = 268) or avoid (n = 269 [1 withdrew]) antiplatelet therapy. The primary outcome
of recurrent ICH affected 22 of 268 participants (8.2%) allocated to antiplatelet therapy
compared with 25 of 268 participants (9.3%) allocated to avoid antiplatelet therapy
(adjusted hazard ratio, 0.87; 95% CI, 0.49-1.55; P = .64). A major vascular event affected 72
participants (26.8%) allocated to antiplatelet therapy compared with 87 participants (32.5%)
allocated to avoid antiplatelet therapy (hazard ratio, 0.79; 95% CI, 0.58-1.08; P = .14).
CONCLUSIONS AND RELEVANCE Among patients with ICH who had previously taken
antithrombotic therapy, this study found no statistically significant effect of antiplatelet
therapy on recurrent ICH or all major vascular events. These findings provide physicians with
some reassurance about the use of antiplatelet therapy after ICH if indicated for secondary
prevention of major vascular events.
TRIAL REGISTRATION isrctn.org Identifier: ISRCTN71907627
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A t least one-third of adults in high-income countries withstroke caused by spontaneous (nontraumatic) intrace-rebral hemorrhage (ICH) are already taking oral anti-
thrombotic (antiplatelet or anticoagulant) drug therapy1 be-
cause of their comorbidities and other risk factors for vascular
disease.2 Even after these risk factors are accounted for, sur-
vivors of spontaneous ICH are at higher risk of myocardial in-
farction and ischemic stroke than the general population,3,4
and their risk of all hemorrhagic or ischemic major vascular
events is higher still at approximately 8% per year.5-7 Anti-
platelet agents may benefit survivors of spontaneous ICH,8,9
but their effect on major vascular events is uncertain.10
A systematic review on June 11, 2021 (eTable 1 in Supple-
ment 1), suggested that the Restart or Stop Antithrombotics
Randomized Trial (RESTART) is the only published random-
ized clinical trial that compared the effects of starting vs avoid-
ing antiplatelet therapy after ICH. RESTART included ICH sur-
vivors who had taken antithrombotic therapy to estimate the
effects of starting vs avoiding antiplatelet therapy on recur-
rent symptomatic ICH and whether this risk might exceed any
reduction of occlusive vascular events.11-13 After a median of
2 years of follow-up of 537 participants, RESTART’s main re-
sult excluded all but a very modest increase in the risk of re-
current ICH with antiplatelet therapy (adjusted hazard ratio
[HR], 0.51; 95% CI, 0.25-1.03; P = .06).14,15 Therefore, the tri-
al’s funder gave permission for the remainder of the funding
award to be used to follow up all surviving participants will-
ing to continue in the trial, which enabled us to extend fol-
low-up for all surviving participants for up to 2 more years to
improve the precision of estimates of effect during 3 years for
most participants and provide information about effects up to
7 years for some participants.
Methods
Study Design
RESTART was an investigator-led, pragmatic, multicenter, pro-
spective, open-label, blinded end point, parallel-group ran-
domized clinical trial at 122 hospitals in the UK.11,12,14,15 The
RESTART Steering Committee and the Academic and Clinical
Central Office for Research and Development approved and
published the trial protocol and the statistical analysis plan
(Supplement 2).11,12 RESTART was approved by the Scotland
A Research Ethics Committee. All data were deidentified be-
fore analysis. The study followed the Consolidated Standards
of Reporting Trials (CONSORT) reporting guideline.
Participants
We included adults (≥18 years of age) who had survived at least
24 hours after spontaneous ICH confirmed by brain imaging
and were receiving antithrombotic therapy for the preven-
tion of occlusive vascular disease at the onset of ICH, after
which therapy was discontinued. Patients, or their nearest rela-
tive or representative if the patient did not have mental ca-
pacity, provided written informed consent in inpatient or out-
patient hospital settings. Participants could be enrolled if they
or their nearest relative, and their physician in secondary care,
were uncertain about whether to start or avoid antiplatelet
therapy and gave written informed consent.12
Randomization and Blinding
Investigators supplied complete information about partici-
pants’ demographic characteristics, race/ethnicity (classified
by investigators with participants to characterize the popula-
tion), comorbidities, functional status, previous antithrom-
botic therapy, ICH, and their preferred antiplatelet therapy into
a database via a secure web interface with in-built validation.
A central computerized randomization system that incorpo-
rated a minimization algorithm randomly assigned partici-
pants (1:1) to start or avoid antiplatelet therapy. A detailed de-
scription of the minimization algorithm was published with
the main results.14 The web interface displayed each partici-
pant’s allocation to starting or avoiding antiplatelet therapy;
if the participant was allocated to start antiplatelet therapy, the
system reminded investigators to prescribe the prespecified
preferred antiplatelet therapy within 24 hours.
Treatment allocation was open to participants, practition-
ers caring for them in primary and secondary care, and local
investigators. Staff conducting follow-up at the trial coordi-
nating center were blinded to treatment allocation. Outcome
event adjudicators were blinded to participant identity, treat-
ment allocation, and drug use. When the main results were
published,14,15 we mailed a summary of them written in plain
English to surviving participants and their primary care prac-
titioners and published them on the trial website in written and
video format.16
Procedures
Participants who had not already undergone magnetic reso-
nance imaging (MRI) and who were able and willing to
undergo brain MRI provided informed consent and under-
went brain MRI according to the trial’s MRI protocol before
randomization. After randomization, 1 of a panel of consul-
tant neuroradiologists (P.M.W., David P. Minks, FRCR,
Dipayan Mitra, MD, Priya Bhatnagar, FRCR, Johann C. du
Plessis, FRCR, or Yogish Joshi, FRCR), blinded to treatment
allocation, used the web-based Systematic Image Review
Key Points
Question What are the long-term effects of antiplatelet therapy
after stroke caused by intracerebral hemorrhage in patients who
were in the pilot phase of the Restart or Stop Antithrombotics
Randomized Trial?
Findings In this randomized clinical trial of 537 participants with
extended follow-up for a median total of 3.0 years (interquartile
range, 2.0-5.0 years), the proportion of participants with
intracerebral hemorrhage recurrence was 8.2% after allocation to
start antiplatelet therapy and 9.3% without antiplatelet therapy, a
nonsignificant difference. There were nonsignificantly fewer major
vascular events among individuals in the group taking antiplatelet
therapy vs the group avoiding antiplatelet therapy (26.8% vs
32.5%).
Meaning After intracerebral hemorrhage associated with
antithrombotic drug use, antiplatelet therapy appears to be safe.
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System tool to review anonymized digital images of diag-
nostic brain computed tomography or MRI to confirm or
refute eligibility and to support the adjudication of cerebral
outcome events.
We restricted starting antiplatelet therapy to 1 or more of
oral aspirin, dipyridamole, or clopidogrel, administered within
24 hours of randomization with doses determined at the dis-
cretion of the consultant responsible for the participant. The
comparator was a policy of avoiding antiplatelet therapy. Par-
ticipants could start or discontinue antithrombotic therapy if
clinically indicated by events during follow-up. We measured
adherence after randomization by recording antiplatelet
therapy use before the first outcome event according to the pre-
ceding clinic or hospital discharge form or follow-up question-
naire. We collected information about blood pressure–
lowering drugs and blood pressure control at discharge and
during follow-up.
We followed up participants by sending a postal question-
naire to their primary care practitioners (who hold a compre-
hensive lifelong medical record for each patient registered with
them), followed by a postal questionnaire to surviving par-
ticipants (or caregivers) who had not withdrawn, to check sur-
vival, medication use, modified Rankin scale score, and the
occurrence of outcomes. We sent questionnaires after ran-
domization at 6 months or 1 year and then annually for up to
7 years. We interviewed participants who did not respond to
the questionnaire by telephone.17,18 Extended follow-up was
approved by the funder on February 25, 2019, by the research
ethics committee on July 12, 2019, and by the sponsor on July
18, 2019, so that accrual of follow-up resumed on July 26, 2019,
and ended on November 30, 2020.
We recorded serious adverse events (that were neither
an outcome event nor an expected complication of stroke)
via investigators if they occurred before hospital discharge
or via primary care practitioners’ annual reports of hospital
admissions. Investigators reported protocol deviations and
violations to the trial coordinating center and the sponsor.
Monitoring included central statistical monitoring of trial
conduct, data quality, and participant safety, supplemented by
triggered onsite monitoring visits if required and detailed
source data verification at the trial coordinating center. We con-
ducted completeness, range, consistency, validation, and logic
checks on all baseline and outcome data from the web-based
case report forms.
Outcomes
The primary outcome was fatal or nonfatal radiologically or
pathologically proven recurrent symptomatic ICH assessed
in all participants (except 1 participant who withdrew before
the first follow-up). The secondary outcomes of major hem-
orrhagic events and major occlusive vascular events were
prespecified.11,12 In the protocol, we had specified a com-
posite secondary outcome of all major vascular events
defined by the Antithrombotic Trialists’ Collaboration (non-
fatal myocardial infarction, nonfatal stroke [ischemic, hem-
orrhagic, or uncertain cause], or death from a vascular
cause).8,12 The process of outcome adjudication was
described in the main report.14,19,20
Statistical Analysis
We aimed to recruit 720 participants and continue their fol-
low-up for at least 2 years to cover several combinations of pub-
lished estimates of the primary outcome event rate in cohort
studies (1.8%-7.4% per year)21 and an up to 4 times propor-
tional increase in the absolute risk of the primary outcome with
the use of antiplatelet therapy in observational studies.22-24
Throughout the recruitment period and during extended fol-
low-up, unblinded trial statisticians supplied the indepen-
dent data monitoring committee with analyses of the accu-
mulating baseline and follow-up data at the same frequency
and for the same purposes as described previously.14 Two stat-
isticians (A.R. and S.L.) and the chief investigator (R.A.-S.S.)
prepared an updated statistical analysis plan for the analysis
of extended follow-up, which was approved by the RESTART
Steering Committee before database lock. All group compari-
sons were made using the intention-to-treat populations. All
group comparisons were made using the intention-to-treat
populations.
We estimated survival in each treatment group using a Ka-
plan-Meier survival analysis of time to first occurrence of a pri-
mary or secondary outcome event during all available fol-
low-up after randomization, censored at death unrelated to an
outcome event or last available follow-up. We quantified com-
pleteness of follow-up as the proportion of participants with
a complete follow-up questionnaire at each planned interval
after randomization and as the proportion of the planned du-
ration of follow-up that was observed.25 After assessing the pro-
portional hazards assumption graphically and including a treat-
ment by log(time) interaction, we compared survival by
allocated treatment using the log-rank test. The primary
method of analysis was to construct an unadjusted Cox pro-
portional hazards regression model and a second model ad-
justed for all 5 covariates included in the minimization algo-
rithm to calculate the HRs. We used the Mann-Whitney test
to compare group summaries of modified Rankin scale scores
by randomized group. We performed sensitivity analyses by
adding symptomatic stroke of uncertain subtype or deaths of
undetermined cause to the primary outcome.
We performed prespecified exploratory subgroup analy-
ses of the primary outcome with statistical tests of interac-
tion to estimate heterogeneity of treatment effect between the
prespecified subgroups: the 5 covariates used by the minimi-
zation algorithm, antithrombotic therapy before ICH, and his-
tory of atrial fibrillation. The unblinded trial statistician (A.R.)
performed statistical analyses with SAS statistical software, ver-
sion 9.4 (SAS Institute Inc). A 2-sided P < .05 was considered
to be statistically significant.
Results
A total of 537 patients (median age, 76.0 years; IQR, 69.0-
82.0 years; 360 [67.0%] male; median time after ICH onset,
76.0 days; IQR, 29.0-146.0 days) were randomly allocated to
start (n = 268) or avoid (n = 269 [1 withdrew]) antiplatelet
therapy. Between May 22, 2013, and May 31, 2018, a total of
562 participants consented to take part in the study from 104
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of 122 activated hospital sites. A total of 268 participants were
randomly assigned to start antiplatelet therapy and 269 to avoid
antiplatelet therapy, of whom all but 1 participant was in-
cluded in the outcome analyses. The flow diagram (Figure 1)
and baseline characteristics (eTables 2 and 3 in Supplement 1)
were unchanged from the main trial results. Extended fol-
low-up ended on November 30, 2020. We obtained 1805 of a
potential 1844 person-years of follow-up (overall complete-
ness, 97.9%) for a median follow-up of 3.0 years (IQR, 2.0-5.0
years) per participant.
Immediate adherence to allocated treatment was good,
with some decrease in adherence over time, but no clear over-
all change between the main results of the trial and when ex-
tended follow-up ended (eTable 4 in Supplement 1). Few par-
ticipants used anticoagulant therapy during follow-up (eTable 5
in Supplement 1). Most participants took at least 1 blood pres-
sure–lowering drug during follow-up and achieved a median
systolic blood pressure of approximately 130 mm Hg, with good
balance by treatment allocation (eTable 6 in Supplement 1). The
proportional hazards assumption was fulfilled for analyses of
primary and secondary outcomes during follow-up, apart from
the composite outcome of any major hemorrhagic or occlu-
sive event.
For the primary outcome, 22 of 268 participants (8.2%) al-
located to start antiplatelet therapy had recurrent ICH com-
pared with 25 of 268 participants (9.3%) allocated to avoid an-
tiplatelet therapy (adjusted HR, 0.87; 95% CI, 0.49-1.55; P = .64)
(Table 1, Table 2, and Figure 2), without a significant risk dif-
ference in any individual year of follow-up (eTable 7 in Supple-
ment 1). This finding was similar in unadjusted and adjusted
models and in 2 sensitivity analyses that involved the addi-
tion of symptomatic stroke of uncertain subtype or death of
undetermined cause (Table 2). At the time of their recurrent
ICH, 3 of the 22 participants (13.6%) in the start antiplatelet
therapy group were not taking an antiplatelet agent, and 6 of
the 25 participants (24.0%) assigned to avoid antiplatelet
therapy were taking an antiplatelet agent. There was no evi-
dence of heterogeneity of the effects of antiplatelet therapy
on the primary outcome in prespecified exploratory sub-
group analyses (eFigure 1 in Supplement 1).
For the composite secondary outcomes, no significant dif-
ferences were found between participants assigned to start vs
avoid antiplatelet therapy during the entire period of fol-
low-up (Table 2). For the composite secondary outcome of all
major vascular events (ie, nonfatal myocardial infarction, non-
fatal stroke [ischemic, hemorrhagic, or uncertain cause], or
death from a vascular cause) as used by the Antithrombotic
Trialists Collaboration,8,12 which seemed to be reduced by start-
ing antiplatelet therapy in the main results of the trial (ad-
justed HR, 0.65; 95% CI, 0.44-0.95; P = .03),14 no statistically
significant reduction was found for the entire period of ex-
tended follow-up (Table 2). However, during the first 3 years
of follow-up when almost all trial participants were followed
up until they were censored or an outcome occurred, signifi-
Figure 1. Flow Diagram
25 Not randomized
6 Ineligible
1 Consented after end of recruitment
7 Health deteriorated
11 Practitioner, patient, or caregiver
uncertain about antiplatelet drug use
1 Withdrew from follow-up
3 Died before discharge 1 Died before discharge
268 Assigned to start antiplatelet therapy
265 First follow-up
259 of 265 Received allocated intervention 
268 Analyzed
269 Assigned to avoid antiplatelet therapy
267 First follow-up




4 Ineligible (prescribed low-dose heparin)
1 Meningioma
5 Hemorrhagic transformation of cerebral infarction
3 Subarachnoid hemorrhage
562 Consented
Reprinted with permission from
RESTART Collaboration.14
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cant differences were found in the cumulative risk of all ma-
jor vascular events between participants assigned to start vs
avoid antiplatelet therapy after 1 year (cumulative risk differ-
ence, −7.0%; 95% CI, −12.6 to −1.4), 2 years (cumulative risk
difference, −8.9%; 95% CI, −15.7 to −2.1), and 3 years (cumu-
lative risk difference, −7.8%; 95% CI, −15.5 to −0.1) (Figure 3;
eTable 7 in Supplement 1).
No differences were found in the distribution of the modi-
fied Rankin scale score during extended follow-up (eTable 8
in Supplement 1). Few serious adverse events occurred, which
were neither outcomes nor expected complications of stroke
(eTable 9 in Supplement 1).
Discussion
During extended follow-up of participants in RESTART for a
median of 3.0 years, survivors of an ICH that occurred while
they were receiving antithrombotic therapy who were as-
signed to start antiplatelet therapy experienced similar num-
bers of ICH recurrences compared with participants assigned
to avoid antiplatelet therapy. Effects on various secondary out-
comes were not significant, but significantly fewer major vas-
cular events occurred after allocation to start antiplatelet
therapy after 1, 2, and 3 years.
Our findings are consistent with the expected effects of an-
tiplatelet therapy.8 However, extended follow-up in RE-
START still lacked the power to detect these effects with pre-
cision, despite a 70% increase in the total person-years of
follow-up from 1064 to 1805, a 34% increase in primary out-
comes from 35 to 47, and a 45% increase in major vascular
events from 110 to 159.14 The change in the nonsignificant mag-
nitude and precision of the effect of antiplatelet therapy on re-
current spontaneous ICH that we have observed after ex-
tended follow-up may reflect the small numbers of these
outcomes in the main results14; the 95% CI of the estimate of
the effect of aspirin on hemorrhagic stroke when used for sec-
ondary prevention of occlusive vascular disease (rate ratio, 1.67;
95% CI, 0.81–3.44) 8 includes the effect of antiplatelet therapy
on recurrent spontaneous ICH in the extended follow-up of RE-
START (adjusted HR, 0.87; 95% CI, 0.49-1.55). Furthermore,
more than half of the reduction in major vascular events ob-
served after starting vs avoiding antiplatelet therapy in the main
results of RESTART (45 vs 65; adjusted HR, 0.65; 0.44-0.95)
was attributable to the difference in recurrent spontaneous ICH
(12 vs 23); the numbers of participants with recurrent sponta-
neous ICH after extended follow-up is similar (22 vs 25), mak-
ing the observed differences in major vascular events in the
first 3 years (eTable 8 in Supplement 1) less driven by differ-
ences in numbers with recurrent ICH.14
To our knowledge, RESTART remains the only com-
pleted randomized clinical trial that compares starting vs
avoiding antiplatelet therapy after ICH.10 We minimized
selection bias by using central, computerized random
sequence generation and concealing allocation on the web
application until all baseline data were entered. Event rates
in RESTART were comparable to community-based studies
in the UK.5 Blood pressure was controlled comparably
between groups throughout follow-up. We minimized attri-
tion bias by achieving greater than 97% completeness of
extended follow-up. We continued to blind outcome asses-
sors and used objective definitions of major outcomes and
independent verification to reduce misclassification of
hemorrhagic and occlusive vascular events and to reduce
the bias that can arise in outcome assessment when treat-
ment allocation is open.26
Limitations
The sample size and number of outcomes in RESTART were
too small to be definitive. Most participants were male.27 Al-
though we did not blind the assigned treatment to partici-
pants and physicians, the outcomes were objective and adju-
dicated blinded to treatment allocation, which minimizes
bias.28 Adherence to the allocated treatment decreased over
time but was greater than 80% even after 5 years of follow-up
and did not seem to be affected by the publication of the main
results. Some of the secondary composite outcomes in-
cluded venous thromboembolism, which may not be af-
fected by antiplatelet therapy that principally reduces the risk
of occlusive arterial events by reducing platelet activation and
aggregation29; this effect may explain why an early effect of
Table 1. Frequencies of the First Occurrence of Primary and Secondary
Outcome Events During Follow-up
Outcome

















6 (2.2) 4 (1.5)
Major extracranial hemorrhage 6 (2.2) 2 (0.7)
Major occlusive vascular events
Ischemic stroke 28 (10.4) 39 (14.6)
Myocardial infarction 11 (4.1) 10 (3.7)
Peripheral arterial occlusion 8 (3.0) 3 (1.1)
Transient ischemic attack 13 (4.9) 26 (9.7)
Retinal arterial occlusion 0 0
Mesenteric ischemia 0 0
Stroke of uncertain subtype 1 (0.4) 5 (1.9)
Carotid, coronary, or peripheral arterial
revascularization procedures
13 (4.9) 6 (2.2)
Venous events
Deep vein thrombosis 8 (3.0) 2 (0.7)
Pulmonary embolism 5 (1.9) 1 (0.4)
Deaths
Fatal outcome event 22 (8.2) 24 (9.0)
Other cardiovascular death 8 (3.0) 13 (4.9)
Sudden cardiac death 3 (1.1) 0
Noncardiovascular deaths 52 (19.4) 53 (19.8)
Deaths of undetermined cause 2 (0.7) 5 (1.9)
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antiplatelet therapy was detected on major vascular events8
but not on other composite outcomes (Table 2). Participants
were recruited from similar state-funded health care services
in 4 countries of the UK, but the generalizability of our find-
ings to other populations is unknown.
These findings alongside published observational
studies3,22-24,30-35 provide reassurance about the use of
long-term antiplatelet therapy after ICH associated with
antithrombotic therapy. Since RESTART’s main results were
published, 1 stroke guideline has recommended, “In
patients with an indication for continued antiplatelet treat-
ment, resuming antiplatelet therapy is reasonable (Evidence
Level B).”36 However, we did not observe a change in par-
ticipants’ adherence during extended follow-up after the
main results were published, so patients and guidelines will
require greater strength and certainty of evidence to change
clinical practice.
A much larger randomized clinical trial could investi-
gate several remaining uncertainties about antiplatelet
therapy after ICH,37-40 including whether there is an overall
reduction in major vascular events after ICH of similar mag-
nitude to that seen in patients without ICH8; whether time
since ICH and duration of antiplatelet therapy modify these
effects41; whether effects vary in other subgroups (such as
lobar ICH loc ation, which is a r isk f ac tor for ICH
recurrence5,21 [eFigures 1 and 2 in Supplement 1], or other
imaging features that may modify risks of recurrent ICH or
ischemic stroke15,42); and whether antiplatelet therapy is
beneficial for ICH survivors without prior antithrombotic
drug use or major vascular events.3,5
Table 2. Risks of First Occurrence of Primary and Secondary Outcome Events During Extended Follow-up
Outcome
No. (%) of participants Unadjusted hazard ratio Adjusted hazard ratio
Start antiplatelet
therapy (n = 268)
Avoid antiplatelet
therapy (n = 268) Estimate (95% CI) P value Estimate (95% CI) P value
Recurrent symptomatic spontaneous
intracerebral hemorrhage
22 (8.2) 25 (9.3) 0.87 (0.49-1.54) .63 0.87 (0.49-1.55) .64
Recurrent symptomatic spontaneous
intracerebral hemorrhage or symptomatic stroke
of uncertain subtype
23 (8.6) 28 (10.4) 0.81 (0.47-1.41) .46 0.81 (0.47-1.41) .46
Recurrent symptomatic spontaneous intracerebral
hemorrhage or death of undetermined cause
25 (9.3) 33 (12.3) 0.76 (0.45-1.27) .29 0.75 (0.45-1.27) .29
All major hemorrhagic events (all types of
symptomatic spontaneous or traumatic
intracranial hemorrhage or symptomatic
major extracranial hemorrhage)
32 (11.9) 30 (11.2) 1.07 (0.65-1.75) .80 1.07 (0.65-1.76) .79
All major occlusive vascular events (ischemic
stroke, myocardial infarction, mesenteric ischemia,
peripheral arterial occlusion, deep vein thrombosis,
pulmonary embolism, or carotid/coronary/
peripheral arterial revascularization procedures)
57 (21.3) 53 (19.8) 1.08 (0.74-1.56) .70 1.09 (0.75-1.59) .64
Major occlusive vascular events
(as proposed in the trial protocol)
65 (24.3) 71 (26.5) 0.90 (0.64-1.26) .53 0.90 (0.64-1.26) .55
Major vascular events (as proposed in the trial
protocol: nonfatal myocardial infarction,
nonfatal stroke, or death from a vascular cause
[including sudden death, pulmonary embolism,
hemorrhage, and death from an unknown cause])
72 (26.8) 87 (32.5) 0.79 (0.58-1.08) .16 0.79 (0.58-1.08) .14
Figure 2. Risk of the First Occurrence of Recurrent Symptomatic
Intracerebral Hemorrhage
0
No. at risk (No. of cumulative events)

































268 (0) 205 (23) 159 (23) 99 (24) 67 (25)233 (17)
268 (0) 211 (13) 161 (15) 111 (17) 65 (21)239 (9)
Avoid
Start
Numbers at risk refer to survivors undergoing follow-up at the start of each year
according to treatment allocation. Plot was censored at 5 years. Cumulative
events indicate the participants in follow-up with a first event.
Figure 3. Risk of the First Occurrence of a Major
Vascular Event
0
No. at risk (No. of cumulative events)






















268 (0) 183 (63) 136 (74) 82 (81) 55 (84)216 (43)
268 (0) 198 (39) 145 (52) 93 (62) 54 (71)230 (24)
Avoid
Start
Numbers at risk refer to survivors under follow-up at the start of each year
according to treatment allocation. Plot was censored at 5 years. Cumulative
events indicate the participants in follow-up with a first event.
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Conclusions
After final, extended follow-up of the only completed ran-
domized clinical trial of antiplatelet therapy after ICH, no sta-
tistically significant increase in the risk of recurrent ICH after
restarting antiplatelet therapy was found. This finding pro-
vides physicians with some reassurance about the use of an-
tiplatelet therapy after ICH if indicated for secondary preven-
tion of major vascular events.
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